Conference Day Two |
Thursday, December 4

9:00 am Check-In & Coffee

9:25 am Chair’s Opening Remarks

Integrating Real-World Evidence Across the Product Lifecycle to Drive Actionable, Cross- Functional Impact

9:30 am The Role of RWE in Integrated Evidence Plans

Synopsis

  • Integration of Real-World Evidence (RWE) into iEP
  • The role and purpose of RWE in iEP
  • Dissemination of case study findings

10:00 am Enhancing Trial Relevance with Big Data & Pragmatic Design: Rethinking Inclusion & Exclusion Criteria

  • Todd Correll Vice President - Clinical Research & Medical Affairs, Vir Biotechnology Inc.

Synopsis

  • Leverage real-world datasets and big data analytics to assess how traditional eligibility criteria may limit trial generalizability and impact patient access
  • Explore the use of pragmatic trial design to better reflect real-world populations, treatment pathways, and comorbidities
  • Share case studies and methodologies for redefining inclusion and exclusion criteria to optimize patient recruitment, retention, and evidence applicability

10:30 am Supporting Data-Driven Decisions with Real-World Evidence for Ultra- Rare Pediatric Neurological Diseases

  • Steve Kymes Director - Health Economics & Outcomes Research, Ionis Pharmaceuticals, Inc.

Synopsis

  • Explore innovative approaches to generating real-world evidence in ultra-rare pediatric neurological conditions, where traditional data is limited
  • Address challenges in evidence generation, including data availability, small sample sizes, data heterogeneity, and follow-up
  • Drive regulatory, clinical, and access decision makers through cross-functional collaborations and data sources tailored to rare pediatric populations

11:00 am Morning Break & Networking

Implementing Patient Voice to Enhance RWE Reliability & Accuracy

11:30 am Capturing the Lived Experience by Integrating Patient-Reported Outcomes into Real-World Data Streams

Synopsis

  • Demonstrating how structured PRO collection enhances clinical relevance and granularity of RWE studies
  • Discussing methodologies for embedding patient-reported data into electronic health records, registries, and digital health platforms
  • Exploring the impact of PROs on treatment effectiveness evaluation, particularly in chronic and rare disease contexts

12:00 pm Roundtable: Embedding the Patient Voice in RWE From Insight to Impact

Synopsis

  • Integrate patient-reported outcomes, preferences, and experiences to enrich RWE datasets and align evidence with real-world clinical value
  • Explore frameworks and tools for capturing structured and unstructured patient voice data across diverse populations and settings
  • Assess the impact of patient-centric RWE on regulatory submissions, payer decisions, and lifecycle evidence generation strategies

12:30 pm Lunch & Networking

Harnessing Innovative Real-World Insights

1:30 pm Leveraging Retrospective Observational Studies for Rapid, Scalable Evidence Generation

  • Biyao Zou Observational Research Manager, Amgen Inc.

Synopsis

  • Outlining best practices for designing retrospective cohort and case-control studies using EHRs and claims data
  • Addressing common biases and confounding factors with methodological safeguards such as propensity scoring and sensitivity analysis
  • Highlighting successful use cases in post-market safety surveillance and comparative effectiveness.

2:00 pm Roundtable: Driving Accountability & Innovation by Clarifying Ownership of Data Quality in a Decentralized RWE Landscape

  • Soham Shah Clinical Digital Transformation Lead - North America, Roche

Synopsis

  • Assessing how the rise of internal RWE hubs, external providers and tech entrants reshapes responsibility for data quality
  • Debating who should own and maintain quality standards pharma, providers, tech platforms, or new RWE custodians
  • Proposing governance frameworks that align data stewardship with end-user needs and regulatory standards

2:30 pm Chair’s Closing Remarks